Sofinnova Partners appoints David Evans as Partner
- Sofinnova strengthens its growth strategy with a high-caliber London-based Partner
- Physician-scientist combining frontline clinical experience, health financing and policy expertise, and a proven track record in venture capital
- Over 20 years in drug development at Bristol Myers Squibb, Eli Lilly, and the Roche Venture Fund as well as in healthcare policy and financing
PARIS, France – July 13, 2026 — Sofinnova Partners (“Sofinnova”), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, announced the appointment of David Evans as Partner. A physician-scientist with deep pharma and drug development expertise, Evans joins from the Roche Venture Fund, where he most recently served as Senior Investment Director. His career spans frontline patient care as a doctor in Australia and with Médecins Sans Frontières, health policy and financing at the World Bank, and roles across the pharmaceutical industry in health economics & outcomes research and drug development before moving into life-sciences investing.
